Tp 3654 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tp 3654. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tp 3654 Today - Breaking & Trending Today

TP-3654 Demonstrates Favorable Tolerability, Early Clinical Activity in R/R Myelofibrosis

The oral selective PIM1 kinase inhibitor TP-3654 appeared to be well tolerated and to show early signals of spleen volume reduction, symptom improvement, and correlating cytokine reductions in patients with relapsed or refractory myelofibrosis, according to preliminary data. ....

North Carolina , United States , Duke University Medical Center , Dynamic International Prognostic Scoring System , Myelofibrosis Symptom Assessment , Pim1 Kinase Inhibitor , Tp 3654 , Phase 1 2 Tp 3654 102 Study ,